Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability
- PMID: 7066887
Methotrexate cytotoxicity for L5178Y/Asn- lymphoblasts: relationship of dose and duration of exposure to tumor cell viability
Abstract
To determine the relative contribution of dose and duration of exposure to methotrexate (MTX) cytotoxicity, suspension cultures of L5178Y/Asn- murine leukemic cells were exposed to 0.1 to 100 microM MTX for 3 to 42 hr. Viability was determined by cloning in soft agar. While there was a linear relationship between dose and MTX cytotoxicity for exposure duration of 3 and 6 hr (r = -0.66), there was a pronounced flattening of this curve at exposure durations of 18 to 42 hr (r = -0.48). Furthermore, there was an excellent correlation (r = -0.85) between MTX cytotoxicity and durations of exposure for 6 to 42 hr (dose range, 1 to 100 microM). Using the linear least-squares method, a best-fit equation for the kinetics of MTX cytotoxicity was determined to be: log viability = 2.25 = 1.76 (log duration) - 0.31 (log dose). In practice, this equation predicts that a 1-log increase in duration of exposure results in almost a 2-log increase in cytotoxicity, whereas a 1-log increase in dose results in only a 0.3-log increase in cytotoxicity. The clinical utility of these data suggest that protracted infusions of lower doses of MTX would be equally as useful as or more useful than short-term high-dose infusions.
Similar articles
-
Prevention of methotrexate cytotoxicity by asparaginase inhibition of methotrexate polyglutamate formation.Cancer Res. 1985 Jan;45(1):217-20. Cancer Res. 1985. PMID: 2578094
-
Proliferation-dependent cytotoxicity of methotrexate in murine L5178Y leukemia.Cancer Res. 1988 Oct 15;48(20):5638-44. Cancer Res. 1988. PMID: 2458828
-
Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells.Cancer Treat Rep. 1981;65 Suppl 4:115-21. Cancer Treat Rep. 1981. PMID: 7049375 Clinical Trial.
-
Effects of ellipticine on cell survival and cell cycle progression in cultured mammalian cells.Cancer Res. 1980 Jul;40(7):2390-9. Cancer Res. 1980. PMID: 6155993
-
[Antineoplastic effect of L-asparaginase].Postepy Hig Med Dosw. 1981 Mar-Apr;35(2):177-87. Postepy Hig Med Dosw. 1981. PMID: 7038650 Review. Polish. No abstract available.
Cited by
-
Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.Cancer Chemother Pharmacol. 1992;29(6):475-9. doi: 10.1007/BF00684851. Cancer Chemother Pharmacol. 1992. PMID: 1568291
-
Accumulation of DNA strand breaks and methotrexate cytotoxicity.Proc Natl Acad Sci U S A. 1984 Sep;81(18):5694-8. doi: 10.1073/pnas.81.18.5694. Proc Natl Acad Sci U S A. 1984. PMID: 6592582 Free PMC article.
-
Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group.J Pediatr Hematol Oncol. 2012 Jan;34(1):e1-7. doi: 10.1097/MPH.0b013e31820ee239. J Pediatr Hematol Oncol. 2012. PMID: 21364468 Free PMC article.
-
Endoscopic local injection of a new drug delivery formulation, anticancer drug bound to carbon particles, for digestive cancers: pilot study.J Gastroenterol. 1997 Apr;32(2):141-7. doi: 10.1007/BF02936359. J Gastroenterol. 1997. PMID: 9085159
-
Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.J Clin Invest. 1994 Nov;94(5):1996-2001. doi: 10.1172/JCI117552. J Clin Invest. 1994. PMID: 7525652 Free PMC article. Clinical Trial.